Welcome to the e-CCO Library!

P474: An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Berger C.1, Semmler J.1, Ruppert J.1, Schulze H.2, Armbruster F.-P.1, Dignass A.2,3, Stein J.*3,4

Created: Wednesday, 20 February 2019, 10:36 AM
P474: Analysis of UC colectomy rates in pre- and post-biologic era in South-East Scotland
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Jenkinson*1, G. R. Jones1, N. Plevris1, M. Lyons2, K. Kirkwood3, C. Lees1

Created: Friday, 22 February 2019, 9:41 AM
P474: Assessing the position of systemic tacrolimus in the treatment of inflammatory bowel disease: systematic review and meta-analysis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Lie*, J. Kreijne, B. Hansen, J. van der Woude

Created: Friday, 22 February 2019, 9:49 AM
P474: Efficacy and safety of anti-TNF and vedolizumab in liver transplant recipients with inflammatory bowel disease (IBD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Bellanger1*, L. Beaugerie2, A. Amiot3, S. Tezenas du Montcel4, C. Duvoux3, D. Samuel5, F. Carbonnel1

Created: Thursday, 21 February 2019, 9:14 AM
P474: Postoperative disease course after appendectomy as experimental treatment for patients with therapy refractory moderate to severe ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Reijntjes, M.(1)*;Heuthorst, L.(1);Stellingwerf, M.(1);d'Haens, G.R.(2);Bemelman, W.A.(1);Buskens, C.J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P474: Postoperative infectious complications in patients with Inflammatory Bowel Disease: experience of a tertiary center
Year: 2021
Source: ECCO'21 Virtual
Authors: Librero Jiménez, M.(1);Ortega Suazo, E.J.(1);Sánchez Capilla, A.D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P474: Prevalence of fecal incontinence and clinical characteristics of IBD patients in remission and treated with biologics – experience from a tertiary referral center
Year: 2022
Source: ECCO'22
Authors: Jelakovic, M.(1);Turk, N.(1);Brinar, M.(1);Barisic, A.(1);Grgic, D.(1);Cukovic-Cavka, S.(1);Krznaric, Z.(1);
Created: Friday, 11 February 2022, 3:52 PM
P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W.J. Sandborn1, J.P. Gisbert2, I. Modesto3, C. Su4, D. Quirk4, R. Mundayat3, X. Guo4, M. Chiorean5, W. Reinisch6

Created: Thursday, 30 January 2020, 10:12 AM
P475: Gastroenterological and reumatological chronic patients: are there differences in individual welfare and quality of life?—a cross-observational study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Stefani, M. G. Vettorato*, G. Lorenzon, T. Marcon, F. Simonetti, A. Rigo, E. V. Savarino, E. De Marchi, R. D’Incà, G. C. Sturniolo

Created: Friday, 22 February 2019, 9:49 AM
P475: High prevalence of severe liver fibrosis in patients with longstanding IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Steenhuis, S. Van der Marel*, A. Van der Meulen- de Jong, J. Maljaars

Created: Thursday, 21 February 2019, 9:14 AM
P475: Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Majumder, S.(1,2);Melanie , L.(2);Joanne , D.(2);Naveen, S.(2);Quraishi, M.N.(2);Cooney, R.(2);Ghosh, S.(3);Iacucci, M.(1,2,4);N Shivaji, U.(1,2,4)*;
Created: Friday, 14 July 2023, 11:05 AM
P475: Profiling the use of Complementary Alternative Medicines among IBD patients
Year: 2022
Source: ECCO'22
Authors: Sudhakar, P.(1);Stiers, R.(1);Dycker, E.D.(2);Geens, P.(2);Paps, A.(2);Lambrechts, T.(2);Keersmaekers, B.(2);Sabino, J.(1,3);Ferrante, M.(1,3);Vermeire, S.(1,3);Verstockt, B.(1,3);
Created: Friday, 11 February 2022, 3:52 PM
P475: Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Facchin*1, A. Buda2, R. Cardin1, R. D'Incà3, F. Zingone3, N. Agbariah1, E. Savarino3

Created: Friday, 22 February 2019, 9:41 AM
P475: Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Lundekvam, J.A.(1);Høivik, M.L.(1);Anisdahl, K.(1);Moum, B.(1);Medhus, A.W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P475: Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fiorino G.*1, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Nagore D.2, Del Rio L.2, Pascual J.2, Martínez A.2, Danese S.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn’s disease: results of the ENTERPRISE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Schwartz1, L. Peyrin-Biroulet2, K. Lasch3, S. Adsul4, S. Danese5

Created: Thursday, 30 January 2020, 10:12 AM
P476: Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Yarur, A.(2);Rubin, D.T.(3);Dubinsky, M.C.(4);Regueiro, M.(5);Irving, P.(6,7);Peyrin-Biroulet, L.(8,9);Goetsch, M.(10);Gu, G.(11);Wu, J.(12);Modesto, I.(13);McDonnell, A.(14);Rabbat, C.J.(15);Green, J.(16);Anthopoulos, P.(17);
Created: Friday, 14 July 2023, 11:05 AM
P476: Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Knyazev1, A. Kagramanova1, D. Kulakov*1, M. Zvyaglova1, A. Parfenov1

Created: Friday, 22 February 2019, 9:41 AM
P476: Disease recurrence patterns in patients undergoing bowel resections for Crohn’s disease.
Year: 2022
Source: ECCO'22
Authors: Ahmed, M.(1);Chacko, J.(1);Zimerly, S.(1);Patel, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P476: Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);Garre, A.(1);Iborra, M.(2);Sierra, M.(3);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);de Castro, L.(6);Boscá-Watts, M.(7);Casanova, M.J.(1);López-García, A.(8);Lorente, R.(9);Rodríguez, C.(10);Carbajo, A.Y.(11);Arroyo, M.T.(12);Gutiérrez, A.(13);Hinojosa, J.(14);Martínez-Pérez, T.(15);Villoria, A.(16);Bermejo, F.(17);Busquets, D.(18);Camps, B.(19);Cañete, F.(20);Manceñido, N.(21);Monfort, D.(22);Navarro-Llavat, M.(23);Pérez-Calle, J.L.(24);Ramos, L.(25);Rivero, M.(26);Angueira, T.(27);Camo, P.(28);Carpio, D.(29);García-de-la-Filia, I.(30);González-Muñoza, C.(31);Hernández, L.(32);Huguet, J.M.(33);Morales, V.J.(34);Sicilia, B.(35);Vega, P.(36);Domènech, E.(20);Gisbert, J.P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM